~~SECURITIES AND EXCHANGE COMMISSION~~UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ~~____________________~~

FORM 8-K

~~CURRENT~~Pursuant to ~~REPORT~~Section 13 or 15(d) of The Securities Exchange Act of 1934

~~PURSUANT~~Date of TOreport ~~SECTION~~(Date of 13earliest ~~OR 15(d~~event reported): September OF8. 2016

~~THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2016~~ Ember Therapeutics, Inc. ~~(Exact name of registrant as specified in its charter)~~

(Exact name of registrant as specified in its charter)

Delaware	033-13474-NY	01-3341552
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

135 East 57th Street, 24th Floor

New York, NY

10022

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (646) 406-6243

___________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (~~17CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (~~17 CFR ~~240~~230.~~14a-12~~425) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

[ ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 1- REGISTRANT’S BUSINESS AND OPERATIONS

Item 1.01 Entry Into A Material Definitive Agreement

On September ~~June 22~~8, 2016 , we entered into ~~a First Amendment~~ toan ~~Distribution,~~Asset ~~License, and Supply~~ Purchase Agreement (the ~~“Amendment”~~"Agreement") with Midwood ~~Knight Therapeutics~~Distributors, Inc., ~~(“Knight”).~~a ~~The~~New ~~Amendment~~York ~~expands the scope of our exclusive distributorship with Knight~~corporation ("Midwood Distributors"). Under ~~the Amendment, the field for which Knight shall~~ ~~act as~~ the ~~exclusive distributor of our products has been expanded from the limited fields of osteoarthritis~~Agreement, ~~chronic~~we ~~kidney~~acquired ~~disease and Alport Syndrome to include~~ all ~~approved human use indications. Further, the licensed products for which Knight will act as~~assets ~~our~~related ~~exclusive distributor has been expanded~~ to ~~include all of our current and future products including BMP-7, MigralexTM,~~Dermasilk ~~and ICX-RHY/VaveltaTM. Finally~~Brands, ~~the~~a ~~exclusively~~line ~~licensed territory for Knight has been expanded to include the Caribbean and Romania, in addition to the existing territories~~ of ~~Canada, Israel, Russia, and Sub~~anti-~~Saharan~~aging ~~Africa~~skin care products.

~~Our~~Under the ~~agreement~~Agreement, ~~with~~we have ~~Knight~~acquired ~~otherwise~~all material ~~remains~~assets currently asowned ~~set~~by ~~forth~~Dermasilk, including all inventory, raw materials, work in process, packaging, the toll ~~Distribution,~~free ~~License~~number, hardware and ~~Supply~~software ~~Agreement~~used ~~filed~~for asordering ~~Exhibit~~and customer ~~10.14~~support, toall ~~our~~intellectual property, ~~Current~~websites, ~~Report~~domain onnames, accounts ~~Form~~receivable ~~8-K~~and ~~filed~~vendor ~~February~~credits, 3contracts, ~~2016~~and all marketing and promotional information and materials.

~~SECTION~~The purchase 9price –for the ~~Financial~~Dermasilk assets ~~Statements~~consisted of common stock and ~~Exhibits~~warrants, paid as follows:

~~Item~~• 2,105,263 shares ~~9.01~~of ~~Financial~~common ~~Statements~~stock at ~~and~~purchase ~~Exhibits~~price of$0.95.

Exhibit No.	Description
10.1	First Amendment to Distribution, License, and Supply Agreement with Knight Therapeutics, Inc.

In addition, we agreed to assume certain liabilities of Dermasilk arising under certain contracts assumed as part of the asset purchase.

~~SIGNATURES~~SECTION 9 – Financial Statements and Exhibits

~~Pursuant to the requirements of the Securities~~Item ~~Exchange~~9.01 ~~Act~~Financial ofStatements ~~1934,~~and ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Exhibits.

Ember Therapeutics, Inc.

Exhibit No.	Description
10.1	Asset Purchase Agreement with Midwood Distributors Inc. for Dermasilk Brand and assets

~~/s/ Joseph Hernandez~~1

~~Joseph Hernandez Executive Chairman~~SIGNATURES

~~Date:~~Pursuant to ~~July~~the 13requirements of the Securities Exchange Act of 1934, ~~2016~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2Dated: September 26, 2016

By: /s/ Joseph Hernandez

Joseph Hernandez

Executive Chairman

Filing Compare · EMBER THERAPEUTICS, INC. - NY